nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advancing Alzheimer's disease drug review as a national priority
|
Perry, Daniel P. |
|
2009 |
5 |
2 |
p. 180-181 2 p. |
artikel |
2 |
Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results
|
|
|
2009 |
5 |
2 |
p. 93-104 12 p. |
artikel |
3 |
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008
|
Khachaturian, Zaven S. |
|
2009 |
5 |
2 |
p. 85-92 8 p. |
artikel |
4 |
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging
|
Schneider, Lon S. |
|
2009 |
5 |
2 |
p. 172-179 8 p. |
artikel |
5 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Alzheimer's disease translational research programs at the National Institute on Aging
|
Petanceska, Suzana |
|
2009 |
5 |
2 |
p. 130-132 3 p. |
artikel |
6 |
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A national registry on aging
|
Petersen, Ronald C. |
|
2009 |
5 |
2 |
p. 105-107 3 p. |
artikel |
7 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” A national registry to identify a cohort for Alzheimer's disease prevention studies
|
Sabbagh, Marwan N. |
|
2009 |
5 |
2 |
p. 128-129 2 p. |
artikel |
8 |
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A proposal to increase participation in Alzheimer's disease clinical trials
|
Ryan, J. Michael |
|
2009 |
5 |
2 |
p. 140-142 3 p. |
artikel |
9 |
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” “Big Asks”: What can be changed to increase and speed progress on Alzheimer's disease research and treatment?
|
Kukull, Walter A. |
|
2009 |
5 |
2 |
p. 137-139 3 p. |
artikel |
10 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Centers of excellence in Alzheimer's disease: It is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease
|
Doody, Rachelle S. |
|
2009 |
5 |
2 |
p. 133-136 4 p. |
artikel |
11 |
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Comments from abroad
|
Korczyn, Amos D. |
|
2009 |
5 |
2 |
p. 157-158 2 p. |
artikel |
12 |
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Establishing a national biomarker database: Utility and incentives
|
Cummings, Jeffrey L. |
|
2009 |
5 |
2 |
p. 108-113 6 p. |
artikel |
13 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Facilitating Alzheimer's disease drug development in the United States
|
Aisen, Paul S. |
|
2009 |
5 |
2 |
p. 125-127 3 p. |
artikel |
14 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Innovations in care that advance Alzheimer's disease drug development
|
Foster, Norman L. |
|
2009 |
5 |
2 |
p. 159-162 4 p. |
artikel |
15 |
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challenges
|
Ringman, John M. |
|
2009 |
5 |
2 |
p. 166-171 6 p. |
artikel |
16 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and stroke
|
Fillit, Howard |
|
2009 |
5 |
2 |
p. 149-153 5 p. |
artikel |
17 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Rationale and recommendations for first evaluating anti-Alzheimer's disease medications in acute brain injury patients
|
Simpkins, James W. |
|
2009 |
5 |
2 |
p. 143-146 4 p. |
artikel |
18 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Recruitment of participants for Alzheimer's disease clinical trials: The role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors
|
Snyder, Peter J. |
|
2009 |
5 |
2 |
p. 122-124 3 p. |
artikel |
19 |
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy import
|
Reisberg, Barry |
|
2009 |
5 |
2 |
p. 154-156 3 p. |
artikel |
20 |
Commentary on “A roadmap for the prevention of dementia II: Leon Thal symposium 2008.” The megacommunity approach to Alzheimer's disease
|
Van Lee, Reggie |
|
2009 |
5 |
2 |
p. 163-165 3 p. |
artikel |
21 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): A new approach to the prevention of Alzheimer's disease
|
Gillette-Guyonnet, Sophie |
|
2009 |
5 |
2 |
p. 114-121 8 p. |
artikel |
22 |
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Who may benefit from disease-modifying studies in Alzheimer's disease?
|
Gauthier, Serge |
|
2009 |
5 |
2 |
p. 147-148 2 p. |
artikel |
23 |
Contents
|
|
|
2009 |
5 |
2 |
p. A3-A5 nvt p. |
artikel |
24 |
Early risk assessment for Alzheimer's disease
|
Carrillo, Maria C. |
|
2009 |
5 |
2 |
p. 182-196 15 p. |
artikel |
25 |
Editorial Board
|
|
|
2009 |
5 |
2 |
p. A6- 1 p. |
artikel |
26 |
Join Advocates for Increased Alzheimer Research Funding at Public Policy Forum: Your Voice Has Never Been More Important
|
|
|
2009 |
5 |
2 |
p. 197-198 2 p. |
artikel |
27 |
Medical and Scientific Advisory Council
|
|
|
2009 |
5 |
2 |
p. A7- 1 p. |
artikel |
28 |
Prevent Alzheimer's disease by 2020: A national strategic goal
|
Khachaturian, Zaven S. |
|
2009 |
5 |
2 |
p. 81-84 4 p. |
artikel |
29 |
Subscriber information page
|
|
|
2009 |
5 |
2 |
p. A2- 1 p. |
artikel |